

Cyclowest Pty Ltd - Initiation of internal construction and fit-out of a radiopharmaceutical manufacturing facility, Bayswater, Perth, WA

Perth, Australia, 12th April, 2022.

Cyclowest, a subsidiary of Cyclowest Holdings Pty. Ltd., is a cyclotron facility being constructed with considerable structural and building service requirements to enable operation of a cyclotron and PIC/S Class C & D sterile laboratories to create radiopharmaceuticals.

A cyclotron is a type of particle accelerator which uses hydrogen protons to spin these via an increasing spiral. This creates a beam of extremely fast protons which bombard other materials and effectively result in a merger of the protons in the nucleus of a target material. This produces a radioisotope which can then be bonded to pharmaceuticals to make radiopharmaceuticals, also known as tracers or imaging agents used in medical services.

The manufacturing and bonding processes occur in clean room laboratories, certified to exacting Good Manufacturing Practice (GMP) standards by the Therapeutic Goods Administration.

Across Perth and regional WA, 10 medical facilities operate clinical imaging Positron Emission Tomography (PET) services which cannot function without cyclotron produced radiopharmaceuticals. WA PET facilities include public hospitals such as Sir Charles Gairdner, Fiona Stanley and the Joondalup Health Campus but also private practices such as the Hollywood Medical Centre, SKG Radiology, Perth Radiological Clinic, QScan, Envision, Genesis Care and Apex Radiology in Bunbury. PET imaging is critical to the care of every oncology patient along their treatment journey but in addition to oncology, PET is also increasingly being used for neurological, dementia and related cognitive impairments and cardiac imaging.

When completed, Cyclowest's facility will expand the manufacturing capacity of Western Australia to support production of radiopharmaceuticals for the benefit of patients across both the public and private sector and also support late-stage clinical trials in collaboration with the pharmaceutical industry. Cyclowest's Founder, local UWA graduate, Prof. Nat Lenzo added, "Across Cyclowest's facilities globally recognised pharmaceutical companies, research institutions, technology/IP providers and diagnostic and treatment clinic operators will come together to significantly advance Australia's capability in radiopharmaceutical manufacturing and our role as a leader in the rapidly growing theranostics field. These facilities will position Cyclowest as a key player for new, longer-life diagnostic and therapeutic radiopharmaceuticals."

The clinical use of PET imaging and theranostics is rapidly increasing with Cyclowest's facilities designed to meet both current demand and future growth of diagnostic and therapeutic radiopharmaceuticals.

In July 2021, [Cyclowest was awarded \\$2.58 million from the Federal Government Modern Manufacturing Initiative \(MMI\)](#). The MMI is a key element of the Australian Government's Modern Manufacturing Strategy, which aims to help Australian manufacturers scale-up, compete internationally and create jobs. The Manufacturing Integration Stream, one of three MMI funding streams, provides funding for small and large projects and for Cyclowest will facilitate the production of new radiopharmaceuticals at its Perth facility.

Cyclowest Holdings Pty. Ltd. is establishing a network of privately owned cyclotron facilities in Australia and New Zealand, equipped to deliver a range of GMP certified radiopharmaceuticals. Cyclowest Holdings will continue to look for commercial and grant funding opportunities to establish facilities capable to serve patients locally, nationally and internationally with its products.

Despite the challenges of COVID, Cyclowest has teamed up with local teams to design and construct its first facility, expected to be operational mid-2023 that will also provide highly skilled, high value positions in medical manufacturing, locally in WA.